SavedAdd your journal

Journals / Zeynep Kamil Tıp Bülteni / 2014 / Cilt: 45 - Sayı: 2

Peritoneal Dialysis Solutions

Perıton Dıyalız Sıvıları

Ebru YILMAZ
Nida DİNÇEL
İPEK KAPLAN BULUT
Sevgi MİR
Pages
84–93
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this review is to describe and to overview the different types of peritoneal dialysissolutions used during PD

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Peritoneal dialysis (PD) is an important kidney replacement therapy for end stage renal disease (ESRD) patients.
📊
Key Findings & Data:Peritoneal membrane viability increases by their less fibrotic and less inflammatory features of new solutions.
💡
Conclusion & Impact:The aim of this review is to describe and to overview the different types of peritoneal dialysissolutions used during PD
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Peritoneal dialysis (PD) is an important kidney replacement therapy for end stage renal disease (ESRD) patients. Patients easily adapt at home based treatment of PD. Standard traditional solutions uses glucose as an osmotic agent. Glucose based dialysis solutions contains high concentrations of glucose. They cause production of glucose degradation products and lactate. They have high osmolality, and low pH. All these features damage to the peritoneum by fibrosis and neoangiogenesis. Newer PD solutions were produced with alternative buffers and osmotic agents (icodextrin or amino acids). They have a higher pH and causes production of fewer glucose degradation products. With the usage of newer PD solutions we can achieve better metabolic controls of patients and body compositions. Peritoneal membrane viability increases by their less fibrotic and less inflammatory features of new solutions. But their effect on patient survival is not clearly identified yet. The aim of this review is to describe and to overview the different types of peritoneal dialysissolutions used during PD

Özet

Periton diyalizi (PD) son dönem böbrek hastaları için önemli bir renal replasman tedavi yöntemidir. Hastalar evde uygulanan PD tedavisine kolayca uyum sağlarlar. Geleneksel standart periton diyaliz solüsyonları osmotic ajan olarak glukoz kullanırlar. Glukoz içeren diyaliz sıvıları yüksek konsantrasyonda glukoz içerirler. Laktat ve glukoz yıkım ürünlerinin oluşmasına neden olurlar. Yüksek osmolalite ve düşük pH'a sahiptirler. Tüm bu sayılan özellikler peritona zarar verir (fibrosis, neoanjiogenez). Yeni PD solüsyonları alternatif tampon sistemleri ve ozmotik ajan kullanırlar (ikodekstrin ve aminoasitler). Yüksek pH'ya sahip olup daha az glukoz yıkım ürünlerinin oluşumuna neden olurlar. Yeni PD solüsyonlarının kullanımı ile daha iyi metabolic kontrol ve vücut kompozisyonu sağlanabilir. Yeni solüsyonların kullanımı daha az fibrozise yol açar ve antiinflamatuvar özelliklerinden dolayı da periton zarı viabilitesini arttırırlar. Ama hasta sağ kalımını artırdıklarına dair kanıt yoktur. Bu derlemenin ile PD için kullanılan farklı tipte periton diyaliz sıvılarının tanımlaması ve gözden geçirilmesi amaçlanmıştır

🔖

Cite This Article

YILMAZ, E., DİNÇEL, N., BULUT, İ. K., MİR, S. (2014). Peritoneal Dialysis Solutions. Zeynep Kamil Tıp Bülteni, Cilt: 45 - Sayı: 2, 84–93. https://ajindex.com/articles/335282

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Elvia Garcia-Lopez, Bengt Lindholm and Simon Davies. An Update on peritonel dialysis solutions. Nature rewiev Nephrology. 8,224-233 (2012).
  2. Aroeira, L. S. et al. Epithelial to mesenchymal transition and peritoneal membrane failure in pe- ritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J. Am. Soc. Nephrol. 18, 2004-2013 (2007).
  3. Boulanger, E. et al. The triggering of human pe- ritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol. Dial. Transplant. 19, 2208-2216 (2004).
  4. Noh, H. et al. Oxidative stress during peritone- al dialysis: implications in functional and structural changes in the membrane. Kidney Int. 69, 2022- (2006).
  5. Zeier, M. et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal ca- vity and enter the systemic circulation? Kidney Int., 298-305 (2003).
  6. Krediet, R. T. & Balafa, O. Cardiovascular risk in the peritoneal dialysis patient. Nat. Rev. Nephrol. 6, -460 (2010). Ates¸, K. et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int. 60, 767-776 (2001).
  7. Lee, H. Y. et al. Superior patient survival for con- tinuous ambulatory peritoneal dialysis patients tre- ated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit. Dial. Int. 25, 248-255 (2005).
  8. Lee, H. Y. et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol. Dial. Transplant. 21, 2893-2899 (2006).
  9. Posthuma, N. et al. Amadori albumin and ad- vanced glycation end-product formation in perito- neal dialysis using icodextrin. Perit. Dial. Int. 21, -51 (2001).
  10. Ho dac Pannekeet, M. M. et al. Peritoneal transport characteristics with glucose polymer ba- sed dialysate. Kidney Int. 50, 979-986 (1996).
  11. Garcia-Lopez, E. & Lindholm, B. Icodextrin me- tabolites in peritoneal dialysis. Perit. Dial. Int. 29, -376 (2009).
  12. Mistry, C. D., Gokal, R. & Peers, E. A rando- mized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investiga- tion of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int. 46, 496-503 (1994). Posthuma N, ter Wee PM, Donker AJM, Oe PL,van Dorp W, Peers EM, Verbrugh HA. Serum di- saccharides and osmolatilty in CCPD patients usind icodextrin or glucose as daytime dwell. Perit Dial Int; 17:602-607. Mi